Skip to Content
Merck
All Photos(1)

Documents

SML3561

Sigma-Aldrich

VCP746

≥98% (HPLC)

Synonym(s):

4-(5-Amino-4-benzoyl-3-(3-(trifluoromethyl)phenyl)thiophen-2-yl)-N-(6-(9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-ylamino)hexyl)benzamide, N-[6-[[4-[5-Amino-4-benzoyl-3-[3-(trifluoromethyl)phenyl]-2-thienyl]benzoyl]amino]hexyl]adenosine, VCP 746, VCP-746

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C41H40F3N7O6S
CAS Number:
1582751-84-5
Molecular Weight:
815.86
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

O=C(C1=CC=C(C=C1)C2=C(C(C(C3=CC=CC=C3)=O)=C(S2)N)C4=CC=CC(C(F)(F)F)=C4)NCCCCCCNC5=C6N=CN(C6=NC=N5)[C@@H]7O[C@@H]([C@H]([C@H]7O)O)CO

Biochem/physiol Actions

VCP746 is an adenosine receptor A1 (A1AR) agonist composed of adenosine linked to the A1AR positive allosteric modulator VCP171, allowing greatly improved affinity (KI = 58.9 nM vs. 2.95 μM/adenosine & 1.55 μM/VCP171) and potency (GTPγS binding induction EC50 = 0.89 nM vs. 93.3 nM/adenosine & 977 nM/VCP171; hA1AR-CHO membrane) via bitopic receptor engagement with both orthosteric and allosteric sites, as well as biased agonism toward inhibition of forskolin-stimulated cAMP over ERK1/2 phosphorylation (hA1AR-CHO) without hA3AR agonist potency. VCP746 protects against ischemia/hypoxia-induced death of rat neonatal ventricular cardiomyocytes (1 μM) and embryonic cardiomyoblasts (300 nM) without affecting isolated rat atrial heart rate.

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist
Valant C, May LT, Aurelio L, Chuo CH, White PJ, Baltos JA, Sexton PM, Scammells PJ, Christopoulos A
Proceedings of the National Academy of Sciences of the USA, 111, 4614-4619 (2014)
Chung H Chuo et al.
Clinical and experimental pharmacology & physiology, 43(10), 976-982 (2016-07-06)
VCP746 is a novel A1 adenosine receptor (A1 AR) biased agonist previously shown to be cytoprotective with no effect on heart rate. The aim of this study was to investigate the potential anti-hypertrophic effect of VCP746 in neonatal rat cardiac

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service